Powered by

Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

Jan 02, 2019 - GlobeNewswire

Merus to retain all global rights outside of ChinaBetta Pharmaceuticals to fund global IND-enabling activities

UTRECHT, the Netherlands, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that it has agreed to grant Betta Pharmaceuticals Co Ltd (SHE: 300558) an exclusive license to develop and co...